Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Monroe Biomedical Research

Neither a doctor nor a teaching hospital

Research payments

$20,369,201

2,151 payments

Through program year 2025, Monroe Biomedical Research is reported as receiving $20,369,201 in research payments, across 2,151 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $4,911,695 381
2024 Research $4,654,186 454
2023 Research $4,140,475 751
2022 Research $2,374,341 450
2021 Research $3,553,560 32
2020 Research $476,509 25
2019 Research $258,434 58

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $11,291,885 73 payments
  2. Alnylam Pharmaceuticals Inc. $2,993,044 1,293 payments
  3. Moderna TX, Inc. $1,869,141 208 payments
  4. Pfizer Inc. $1,659,264 163 payments
  5. Indivior Inc. $564,082 207 payments
  6. Teva Pharmaceuticals USA, Inc. $470,148 34 payments
  7. Novartis Pharmaceuticals Corporation $414,237 2 payments
  8. American Regent $172,375 17 payments
  9. Verona Pharma, Inc. $169,305 20 payments
  10. Merck Sharp & Dohme Corporation $150,320 7 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized, Double Blind, Placebo Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Ly3819253 and Ly3832479 in Participants With Mild to Moderate Covid-19 Illness $2,548,348 4 payments
  2. Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) $2,195,178 1,127 payments
  3. A Study of Remternetug Versus Placebo in Early Alzheimer's Disease Participants at Risk for Cognitive and Functional Decline $1,099,653 4 payments
  4. A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate Covid-19 Illness (Blaze-4) $1,001,002 3 payments
  5. A Master Protocol for A Randomized, Controlled, Clinical Trial of Multiple Interventions for Chronic Weight Management in Adult Participants With Obesity Or Overweight $926,987 4 payments
  6. A Phase 2, Parallel-Group, Double-Blind Study to Investigate Weight Management With Ly3549492 Once Daily Compared With Placebo in Adult Participants With Obesity Or Overweight $726,850 4 payments
  7. A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. $723,346 20 payments
  8. A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 $716,139 104 payments
  9. A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease $702,497 2 payments
  10. A Phase 2, Parallel-Group, Double-Blind Study to Investigate Weight Management With Ly3841136 Compared With Placebo in Adult Participants With Obesity Or Overweight $696,028 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record